Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 2

Date

26 Feb 2019

Session

Proffered Paper session: New and early developments with new concepts

Presenters

Antoine Hollebecque

Citation

Annals of Oncology (2019) 30 (suppl_1): i4-i9. 10.1093/annonc/mdz029

Authors

A. Hollebecque1, J.S. de Bono2, R. Plummer3, N. Isambert4, P. Martin-Romano1, E. Baudin1, S. Mora5, E. Filvaroff6, M. Lamba7, Z. Nikolova5

Author affiliations

  • 1 Ditep, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 The Institute of Cancer Research and Royal Marsden, London/GB
  • 3 Northern Institute for Cancer Research, NE2 4HH - Newcastle upon Tyne/GB
  • 4 Centre Georges-François Leclerc, 21000 - Dijon/FR
  • 5 Celgene Institute for Translational Research Europe, 41092 - Seville/ES
  • 6 Celgene Corporation, San Francisco/US
  • 7 Celgene Corporation, Summit/US
More

Resources

CC-90011 is a potent, selective, reversible oral inhibitor of the epigenetic target, lysine-specific demethylase 1A (LSD1) that has demonstrated anti-proliferative activity against cancer cells in vitro and in patient-derived xenograft models.

Resources from the same session

Proffered Paper session 2

Presenter: Danique Giesen

Session: Proffered Paper session: New and early developments with new concepts

Resources:

Abstract

Proffered Paper session 2

Presenter: Quan Sing Ng

Session: Proffered Paper session: New and early developments with new concepts

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings